Enhancing the Anti-Tumor Activity of Breast Cancer-Specific Cytotoxic T Lymphocytes
Abstract
Directing the immune system to attack tumors represents a potential powerful non-toxic approach for the treatment of breast cancer. Our goal is to ultimately engineer the interleukin-2 receptor (IL-2R) in cytotoxic T cells (CTL) to control signal transduction through this receptor and to improve the in vivo efficacy upon adoptive transfer to a tumor-bearing host. To this aim we have prepared a series of chimeric IL-2R constructs and show that signaling of one such pair appears to be induced by a small molecular weight dimerizing drug. We also established a sensitive in vivo animal tumor model system to be used to characterize such engineered" CTL. The initial studies in this model indicate that unprimed tumor-specific T cells are essentially ignorant of growing tumor in vivo. By contrast, tumor growth is initially inhibited when adoptively transferred to tumor-bearing mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1999
- Accession Number
- ADA381119
Entities
People
- Thomas R. Malek
Organizations
- University of Miami